Margaret Hubbell, MD
Cornea and External Diseases Specialist · Texarkana, TXNPI 1821452681
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Amgen at 48.5% of the total. Reporting peaked in 2022 at $1,838 and has fallen 97.5% since, to $46 in 2025.
Across 66 payments — averaging $59.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$398
- Alcon$345
- Biotissue Holdings Inc.$247
- Genentech USA, Inc.$150
- Coherus Oncology, Inc.$139
- plus $729 from 14 others
What the payments were for
- Speaking & faculty fees$1,74045%
- Food & beverage$2,15955%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $1,890 |
| AbbVie(2 entities) | 13 | $398 |
| Alcon | 9 | $345 |
| Biotissue Holdings Inc. | 12 | $247 |
| Genentech USA, Inc. | 1 | $150 |
| Coherus Oncology, Inc. | 5 | $139 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $123 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $114 |
| Glaukos Corporation | 1 | $112 |
| Ivantis, Inc | 4 | $101 |
| Sandoz | 2 | $51 |
| Ocular Therapeutix, Inc. | 2 | $44 |
| Rxsight Inc | 2 | $40 |
| Rayner Intraocular Lenses Limited | 2 | $39 |
| Oyster Point Pharma, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $17 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| NEW World Medical,inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,866
- VABYSMO$150
- ENVISTA$123
- STELLARIS$123
- AcrySof IQ PanOptix$121
- iStent inject Trabecular Micro-Bypass Stent System$112
- Clareon$111
- XEN GLAUCOMA TREATMENT SYSTEM$110
How this compares
$3,899 in reported general payments places this provider in the 75th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 17 | $17,991 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $8,471 |
| LumiganBimatoprost | 19 | $8,251 |
| VyzultaLatanoprostene Bunod | 15 | $6,489 |
| Timolol Maleate | 79 | $3,618 |
| Latanoprost | 500 | $3,551 |
| Travoprost | 42 | $3,468 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $3,339 |
| Brinzolamide | 11 | $2,537 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 129 | $2,016 |
| Prednisolone Acetate | 56 | $1,735 |
| MoxifloxacinMoxifloxacin Hcl | 35 | $869 |
| Brimonidine Tartrate | 114 | $775 |
| Acetazolamide | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $17 | $24,48032 claims |
| AbbVieLumigan, Combigan | $398 | $11,59037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in Texarkana
- Forrest SwannWaco$111K
- Stella KimHouston$58K
- Rachel GelmanMcAllen$54K
- Ravi PatelRound Rock$9K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Ardalan SharifiGalveston$3K
- Amar BhatBeaumont$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.